Cargando…

Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources

BACKGROUND: Real-world data (RWD) has been a valuable addition to the scientific literature regarding treatment pathways, clinical outcomes and characteristics of patients with retinal diseases in recent years. Registries, observational studies and patient databases are often used for real-world res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daien, Vincent, Eldem, Bora M., Talks, James S., Korobelnik, Jean-Francois, Mitchell, Paul, Finger, Robert P., Sakamoto, Taiji, Wong, Tien Yin, Evuarherhe, Obaro, Carter, Gemma, Carrasco, Joao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796465/ https://www.ncbi.nlm.nih.gov/pubmed/31619195 http://dx.doi.org/10.1186/s12886-019-1208-9

Ejemplares similares

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
por: Finger, Robert P., et al.
Publicado: (2020)

Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
por: Daien, Vincent, et al.
Publicado: (2021)

Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
por: Korobelnik, Jean-François, et al.
Publicado: (2020)

Adherence to HIV treatment regimens: systematic literature review and meta-analysis
por: Altice, Frederick, et al.
Publicado: (2019)

Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
por: Korobelnik, Jean-François, et al.
Publicado: (2021)

MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
por: Mitchell, Paul, et al.
Publicado: (2021)

Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review
por: Okada, Mali, et al.
Publicado: (2021)

2-Year Real-World Outcomes with Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: Literature Review and Meta-analysis of Patient-Relevant Outcomes
por: Carrasco, Joao, et al.
Publicado: (2021)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Communicating with patients requiring anti-VEGF intravitreal injections and their families during the COVID-19 pandemic: an update
por: Korobelnik, Jean-François, et al.
Publicado: (2021)

Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19
por: Stone, Lydia G., et al.
Publicado: (2020)

Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment
por: Golan, Shani, et al.
Publicado: (2014)

Professional medical writing support and the quality, ethics and timeliness of clinical trial reporting: a systematic review
por: Evuarherhe, Obaro, et al.
Publicado: (2019)

The Role of the Wnt Pathway in VEGF/Anti-VEGF-Dependent Control of the Endothelial Cell Barrier
por: Li, Yueru, et al.
Publicado: (2021)

The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus
por: Danese, Carla, et al.
Publicado: (2023)

Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion
por: Abri Aghdam, Kaveh, et al.
Publicado: (2017)

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
por: Sheth, Jay U, et al.
Publicado: (2021)

Effects of anti-VEGF agents on rat retinal Müller glial cells
por: Guo, Bin, et al.
Publicado: (2010)

Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
por: Seah, Ivan, et al.
Publicado: (2020)

An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent
por: Su, Er-Ning, et al.
Publicado: (2012)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
por: Zhao, Yue, et al.
Publicado: (2018)

Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy
por: Takayama, Kei, et al.
Publicado: (2021)

Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus
por: Chou, Yu-Bai, et al.
Publicado: (2023)

The management of neovascular age‐related macular degeneration: A systematic literature review of patient‐reported outcomes, patient mental health and caregiver burden
por: Gale, Richard P., et al.
Publicado: (2022)

Anti-VEGF and Beyond
por: Bertelmann, T., et al.
Publicado: (2017)

Outer retinal tubulation in diabetic macular edema following anti-VEGF treatment
por: Al-Halafi, Ali M
Publicado: (2015)

Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections
por: Levin, Ariana M, et al.
Publicado: (2017)

Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
por: Bertelmann, Thomas, et al.
Publicado: (2017)

Correction: Use of biomaterials for sustained delivery for anti-VEGF to treat retinal diseases
por: Seah, Ivan, et al.
Publicado: (2020)

Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
por: Wallsh, Josh O., et al.
Publicado: (2021)

Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis
por: Xu, Manhong, et al.
Publicado: (2022)

Observation, laser photocoagulation or anti-VEGF therapy in the management of retinal arterial macroaneurysms
por: Wang, Yuelin, et al.
Publicado: (2022)

Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
por: Bhatia, Devangna, et al.
Publicado: (2021)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema, Muhammad Raza, et al.
Publicado: (2021)

Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury
por: Touzani, F., et al.
Publicado: (2019)

Early anti-VEGF treatment for radiation maculopathy and optic neuropathy: lessons learned
por: Powell, Brittany E., et al.
Publicado: (2022)

Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
por: Deissler, Heidrun L., et al.
Publicado: (2015)

Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era
por: Hsu, Ya-Jui, et al.
Publicado: (2014)

Mature vessel occlusion after anti-VEGF treatment in a retinal arteriovenous malformation
por: Chuang, Lan-Hsin, et al.
Publicado: (2013)

Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture
por: Filek, Richard, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mad8i1uraggcbqp2j9ovgtmo8i